Researchers at the University of Colorado (UC) Denver, Anschutz Medical Campus, have discovered a novel combination treatment strategy that could offer new hope to ovarian cancer patients who stop responding to existing PARP inhibitor (PARPi) therapies.
The strategy combines a PARP inhibitor, a targeted drug used to treat certain types of ovarian cancer, with a novel indirect WNT inhibitor, SM08502 (cirtuvivint), to attack cancer from two directions. SM08502 is a dual CDC-like kinase and dual-specificity tyrosine phosphorylation–regulated kinase inhibitor. In a newly reported study, the researchers report on tests evaluating therapy combining SM08502 with PARPi in multiple resistant models of homologous recombination–deficient high-grade serous carcinoma (HGSC). The team has also advanced from the laboratory to a Phase I clinical trial on the campus.
“I began my career focused on understanding why ovarian cancer becomes resistant to therapy. PARP inhibitors have been a cornerstone of my research,…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
